PI3 Kinase p85 Alpha (PIK3R1) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 03 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for PI3K Pathway Modulator Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for PIK3R1 (p85α) drug discovery. Select your modality below:

Component / Network Product Description Product Link
Wild-Type Antigen PIK3R1 Full-Length & SH2 Domain Constructs (N-SH2, C-SH2). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed for native folding. View PIK3R1 Products
Mutant Antigen PIK3R1 Cancer Hotspot Mutant Proteins: R348*, R460*, R574*, and other truncation/missense variants (e.g., rs3730089). >95% purity, Endotoxin <1 EU/µg. Sequence Verified. View PIK3R1 Products
Gene Delivery PIK3R1 Promise-ORF / Lentivirus (WT & Mutant). Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. High titer. View PIK3R1 Products
Benchmark Antibody Anti-PIK3R1 Recombinant Antibody (Human IgG1 format available). Validated for Western blot, IP, and target engagement. View PIK3R1 Products
Validator (siRNA) PIK3R1 siRNA Set. Three unique target-specific siRNAs for knockdown verification and specificity control. View PIK3R1 Products
Interactor A PIK3CA (p110α) Recombinant Protein. Obligate catalytic partner for p85α-p110α heterodimer reconstitution and PPI disruption assays. Full-length with kinase activity. View PIK3CA Products
Interactor B PIK3CB (p110β) Recombinant Protein. For isoform specificity studies (p110α vs p110β binding). View PIK3CB Products
Pathway Partner PTEN Recombinant Protein. Tumor suppressor phosphatase; negative regulator of PI3K pathway. For combination therapy and resistance studies. View PTEN Products
Downstream Kinase AKT1 Recombinant Protein. Direct downstream effector for functional pathway readout. View AKT1 Products
Ortholog Control PIK3R2 (p85β) Recombinant Protein. For isoform counter-screening in selectivity assays. View PIK3R2 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
PPI Disruption Assay (p85α/p110α heterodimer) Full-length and domain-specific (N-SH2, C-SH2) PIK3R1 proteins with >95% purity, HEK293 expressed for native conformation, verified by SPR/BLI.
Mutant vs Wild-Type Selectivity Screening Literature-relevant PIK3R1 mutant panel (R348*, R460*, R574*, missense variants) with Sequence Verification and Theoretical MW confirmation.
Isoform Counter-Screening (p85α vs p85β) Ortholog panel: PIK3R1 and PIK3R2 proteins strictly verified by mass spec for selectivity profiling.
Lack of Mutant-Specific Controls Purified hotspot mutant proteins for assay development and cellular validation.
Cellular Context and Pathway Validation Lentivirus premade particles (WT & mutant) for stable cell line construction; Validated siRNA sets for knockdown specificity.
Off-target Toxicity (False positives) Orthogonal validation with siRNA and rescue experiments using ORF lentivirus.
Conformational Stability Assay Thermostable wild-type PIK3R1 protein for CETSA and biophysical studies.

Live PIK3R1 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic paradigm for PI3K pathway modulation is shifting from broad-spectrum catalytic p110 inhibition to highly selective, mutant-specific, and allosteric strategies targeting the regulatory subunit p85α. PIK3R1 harbors recurrent oncogenic mutations (e.g., R348*, R574*) in endometrial, breast, and colorectal cancers that disrupt the autoinhibitory interface with p110α, leading to constitutive pathway activation. First-generation PI3K inhibitors suffer from severe dose-limiting toxicities (hyperglycemia, rash), driving R&D toward protein-protein interaction (PPI) disruptors, mutant-selective allosteric modulators, and targeted degradation (PROTACs). Key players include Relay Therapeutics (allosteric), Novartis, AstraZeneca, and emerging biotechs focused on the p85/p110 interface. Future directions include mutant-selective degraders, combination therapies (with AKT/mTOR or immune checkpoint inhibitors), and gene therapy for rare immunodeficiency (SHORT syndrome).

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule PPI Inhibitor / Allosteric Novartis, Relay Therapeutics, Early Biotech Solid Tumors (Breast, Endometrial, Colorectal) PPI Disruption Assay (Needs high-purity p85/p110 proteins)
Isoform-Selective Disruptor Structure-based biotechs Solid Tumors Counter-Screening Panel (Needs PIK3R1 vs PIK3R2 orthologs)
PROTAC / Molecular Glue Emerging Biotechs PIK3R1-Mutant Cancers Mutant-Selective Screening & Ternary Complex (Needs native folding domains)
Combination Therapy (PI3K + AKT/mTOR) AstraZeneca, Bayer Refractory Cancers / GBM Cellular Readout (Needs stable lentiviral cell lines & siRNA)
Gene Therapy (Knock-in) Academic Research Rare Immunodeficiency (SHORT syndrome) Functional Validation (Needs lentivirus for stable mutant expression)